NCT01653756View on ClinicalTrials.gov

A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Asthma
Interventions
DRUG

IPI-145, a PI3K Inhibitor

Active drug

DRUG

Placebo to match IPI-145

Comparator

Trial Locations (4)

Unknown

Investigational Site, Berlin

Investigational Site, Großhansdorf

Investigational Site, Wiesbaden

Investigational Site, Harrow

All Listed Sponsors
lead

SecuraBio

INDUSTRY

NCT01653756 - A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects | Biotech Hunter | Biotech Hunter